Generic Name and Formulations:
Hepatitis A inactivated 720 ELISA Units (EL.U.), hepatitis B surface antigen (recombinant) 20mcg; per mL; susp for IM inj; aluminum adsorbed; contains trace amounts of thimerosal, formalin, neomycin, yeast protein.
Indications for TWINRIX:
Hepatitis A and hepatitis B immunization.
≥18yrs: 1 inj IM in deltoid area at 0-, 1-, and 6 months. Alternate 4-dose schedule: 1 inj IM in deltoid area at 0-, 7-, and 21 to 30-days followed by booster dose at month 12.
<18yrs: not recommended.
May defer in acute febrile illness or active infection. Bleeding disorders. Thrombocytopenia. Immunodeficiency: may get suboptimal response. Have epinephrine (1:1000) inj available. If given with immune globulin, use separate syringe and different site. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy.
Inj site reactions, headache, fatigue, GI upset, fever.
Register pregnant patients exposed to Twinrix by calling (888) 452-9622. Report adverse events to VAERS by calling (800) 822-7967.
Single-dose vials—1, 10; Single-dose prefilled syringes—5
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|